Abstract:BACKGROUND:Medulloblastoma is the most common malignant pediatric brain tumor and group 3 subtype medulloblastoma (G3-MB) exhibits the worst prognosis. Super enhancers (SEs) are large clusters of enhancers that play important roles in cancer through transcriptional control of cell identity genes, oncogenes and tumor-dependent genes. Dissecting SE-driven transcriptional dependencies of cancer leads to identification of novel oncogenic mechanisms, therapeutic strategies and targets.METHODS:Integrative SE analyses of primary tissues and patient-derived tumor cell lines of G3-MB were performed to extract the conserved SE-associated gene signatures and their oncogenic potentials were evaluated by gene expression, tumor-dependency and patient prognosis analyses. SE-associated subtype-specific upregulated tumor-dependent genes, which were revealed as members of SE-driven core transcriptional regulatory network of G3-MB, were then subjected to functional validation and mechanistic investigation. SE-associated therapeutic potential was further explored by genetic or pharmaceutical targeting of SE complex components or SE-associated subtype-specific upregulated tumor-dependent genes individually or in combination, and the underlying therapeutic mechanisms were also examined.RESULTS:The identified conserved SE-associated transcripts of G3-MB tissues and cell lines were enriched of subtype-specifically upregulated tumor-dependent genes and MB patients harboring enrichment of those transcripts exhibited worse prognosis. Fourteen such conserved SE-associated G3-MB-specific upregulated tumor-dependent genes were identified to be members of SE-driven core transcriptional regulatory network of G3-MB, including three well-recognized TFs (MYC, OTX2 and CRX) and eleven newly identified downstream effector genes (ARL4D, AUTS2, BMF, IGF2BP3, KIF21B, KLHL29, LRP8, MARS1, PSMB5, SDK2 and SSBP3). An OTX2-SE-ARL4D regulatory axis was further revealed to represent a subtype-specific tumor dependency and therapeutic target of G3-MB via contributing to maintaining cell cycle progression and inhibiting neural differentiation of tumor cells. Moreover, BET inhibition with CDK7 inhibition or proteasome inhibition, two combinatory strategies of targeting SE complex components (BRD4, CDK7) or SE-associated effector gene (PSMB5), were shown to exhibit synergistic therapeutic effects against G3-MB via stronger suppression of SE-associated transcription or higher induction of ER stress, respectively.CONCLUSIONS:Our study verifies the oncogenic role and therapeutic potential of SE-driven transcriptional dependencies of G3-MB, resulting in better understanding of its tumor biology and identification of novel SE-associated therapeutic strategies and targets.

Effects of super-enhancers in cancer metastasis: mechanisms and therapeutic targets

Pathogenic role of super-enhancers as potential therapeutic targets in lung cancer

Super-enhancer in Prostate Cancer: Transcriptional Disorders and Therapeutic Targets

Dissecting Super-Enhancer Driven Transcriptional Dependencies Reveals Novel Therapeutic Strategies and Targets for Group 3 Subtype Medulloblastoma.

Targeting complexes of super-enhancers is a promising strategy for cancer therapy

Super-enhancers complexes zoom in transcription in cancer

Targeting Complexes of Super‑enhancers is a Promising Strategy for Cancer Therapy (Review)

The Emerging Role of Super Enhancer-Derived Noncoding RNAs in Human Cancer

Super-enhancers: a new frontier for epigenetic modifiers in cancer chemoresistance

Functions and Clinical Significance of Super-Enhancers in Bone-Related Diseases

Super-enhancers: Implications in gastric cancer

Super-enhancers: A New Frontier for Glioma Treatment

Super enhancer lncRNAs: a novel hallmark in cancer

Transcriptional super-enhancers control cancer stemness and metastasis genes in squamous cell carcinoma

Super-enhancer omics in stem cell

Functional characterization and clinical significance of super-enhancers in lung adenocarcinoma

EphA2 Super-Enhancer Promotes Tumor Progression by Recruiting FOSL2 and TCF7L2 to Activate the Target Gene EphA2

Metabolic reprogramming directed by super-enhancers in tumors: An emerging landscape.

Myeloma-specific Superenhancers Affect Genes of Biological and Clinical Relevance in Myeloma.

Abnormal Activations of Super-Enhancers Enhance the Carcinogenicity in Lung Adenocarcinoma

Targeting super-enhancer activity for colorectal cancer therapy